SCHEMBL6495585

SCHEMBL6495585

CCOc1ccc(COS(C)(=O)=O)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 5/20 0.42
HPGD P15428 4/20 0.42
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA2 P00918 1/20 0.40
NQO1 P15559 1/20 0.39
CYP1A2 P05177 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
PDIA6 Q15084 1/20 0.39
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
HSD17B10 Q99714 4/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3173845 0.82 S1PR1 (0.52) HPGDCA12CA1CA7CA9
SCHEMBL6492124 0.82 LMNA (0.42) ALDH1A1KDM4ECA12CA1CA7
SCHEMBL13110336 0.79 NQO1 (0.52) ALDH1A1KDM4EHPGDCA12CA1
SCHEMBL5936680 0.77 S1PR1 (0.42) HPGDPDIA6PKMSMN1; SMN2L3MBTL1
SCHEMBL1015757 0.76 PYCR1 (0.40) ALDH1A1KDM4ECA1CA2SMN1; SMN2
SCHEMBL18199325 0.75 CA12 (0.45) ALDH1A1CA12CA1CA7CA9
SCHEMBL20743498 0.75 NQO1 (0.52) ALDH1A1KDM4ECA12CA1CA7
SCHEMBL5067887 0.73 CHRM2 (0.47) CA1CA7CA9CA2CA14
SCHEMBL30484250 0.73 NQO1 (0.48) ALDH1A1KDM4EHPGDNQO1HSD17B10
SCHEMBL3718805 0.73 NQO1 (0.48) ALDH1A1KDM4EHPGDNQO1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD ALDH1A1 96/4885KDM4E 760/4885HPGD 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.